title: Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b.
abstract: Polysaccharide-protein conjugates as vaccines have proven to be very effective in preventing Haemophilus influenzae type b infections in industrialized countries. However, cost-effective technologies need to be developed for increasing the availability of anti-H. influenzae type b vaccines in countries from the developing world. Consequently, vaccine production with partially synthetic antigens is a desirable goal for many reasons. They may be rigidly controlled for purity and effectiveness while at the same time being cheap enough that they may be made universally available. We describe here the antigenicity and immunogenicity of several H. influenzae type b synthetic oligosaccharide-protein conjugates in laboratory animals. The serum of H. influenzae type b-immunized animals recognized our synthetic H. influenzae type b antigens to the same extent as the native bacterial capsular polysaccharide. Compared to the anti-H. influenzae type b vaccine employed, these synthetic versions induced similar antibody response patterns in terms of titer, specificity, and functional capacity. The further development of synthetic vaccines will meet urgent needs in the less prosperous parts of the world and remains our major goal.
authors.affiliation: Center for the Study of Synthetic Antigens, Facultad de Química, Universidad de La Habana, Havana, Cuba 10400. violeta@fq.uh.cu.
authors.forename: V
authors.initials: V
authors.lastname: Fernández-Santana
authors.forename: Félix
authors.initials: F
authors.lastname: Cardoso
authors.forename: Arlene
authors.initials: A
authors.lastname: Rodriguez
authors.forename: Tania
authors.initials: T
authors.lastname: Carmenate
authors.forename: Luis
authors.initials: L
authors.lastname: Peña
authors.forename: Yuri
authors.initials: Y
authors.lastname: Valdés
authors.forename: Eugenio
authors.initials: E
authors.lastname: Hardy
authors.forename: Fatme
authors.initials: F
authors.lastname: Mawas
authors.forename: Lazaro
authors.initials: L
authors.lastname: Heynngnezz
authors.forename: Maria C
authors.initials: MC
authors.lastname: Rodríguez
authors.forename: Ignacio
authors.initials: I
authors.lastname: Figueroa
authors.forename: Janoi
authors.initials: J
authors.lastname: Chang
authors.forename: Maria E
authors.initials: ME
authors.lastname: Toledo
authors.forename: Alexis
authors.initials: A
authors.lastname: Musacchio
authors.forename: Ibis
authors.initials: I
authors.lastname: Hernández
authors.forename: Mabel
authors.initials: M
authors.lastname: Izquierdo
authors.forename: Karelia
authors.initials: K
authors.lastname: Cosme
authors.forename: Rene
authors.initials: R
authors.lastname: Roy
authors.forename: V
authors.initials: V
authors.lastname: Verez-Bencomo
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D005260:Female; D018073:Haemophilus Vaccines / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009844:Oligosaccharides / Q000276:immunology*; D010428:Pentosephosphates / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D018074:Vaccines, Conjugate / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; D009844:Oligosaccharides; D010428:Pentosephosphates; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic; C003191:polyribose phosphate